Last updated on February 2018

A Multinational Randomized Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Brief description of study

The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).

Clinical Study Identifier: NCT01630733

Contact Investigators or Research Sites near you

Start Over

Oncogenex Pharmaceuticals

Oncology Centre Number 2
Sochi, Russian Federation
  Connect »